AbbVie’s Skyrizi Checks One Last Box With Phase III Success In Ulcerative Colitis
UC Is Final Planned Indication For IL-23 Inhibitor
Executive Summary
Already approved in Crohn’s disease, Skyrizi now has positive Phase III results in ulcerative colitis with more data expected this year in UC as the field grows more crowded with anti-IL-23 options.
You may also be interested in...
Roche Makes Play For Bowel Disease Leadership With $7.1bn Roivant Deal
The Swiss pharma company has followed Merck & Co. and Sanofi by buying into the TL1A-inhibitor class, with pharma chief Teresa Graham confident RVT-3101 could be its next best-in-class blockbuster
AbbVie’s Skyrizi Bests Stelara Head-To-Head In Crohn’s
Data showing superiority on endoscopic remission and non-inferiority on clinical remission could position AbbVie’s IL-23 inhibitor to move ahead of Stelara in treatment paradigm.
AstraZeneca’s IBD Hopes Deflated Amid Evolving Market And Pipeline Competition
The major’s attempt to break into Crohn’s disease and ulcerative colitis has been cut short as a highly competitive market and pipeline, intensified by the entrance of biosimilars, renders further development of brazikumab impractical.